RayzeBio inc (DELISTED) (RYZB:DL)
62.49
0.00 (0.00%)
USD |
NASDAQ |
Mar 06, 16:00
RayzeBio SG&A Expense (Quarterly): 3.481M for Sept. 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 3.481M |
| December 31, 2022 | 2.699M |
| Date | Value |
|---|---|
| September 30, 2022 | 2.122M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.122M
Minimum
Sep 2022
3.481M
Maximum
Sep 2023
2.767M
Average
2.699M
Median
Dec 2022
SG&A Expense (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 2.367B |
| Karuna Therapeutics Inc (DELISTED) | 47.39M |
| Ambrx Biopharma Inc (DELISTED) | 9.41M |
| Pfizer Inc | 3.495B |
| Mirati Therapeutics Inc (DELISTED) | 72.00M |